In vitro and cell based assays for measuring the activity of botulinum neurotoxins
Patent Information
- Application Number
- IN201917017407
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-10-20
- Filing Date
- 2019-05-01
- Publication Date
- 2026-07-30
- Estimated Expiration
- 2037-10-19
Abstract
Description
[0001] The present application claims the benefit of United States Provisional Application Number 62 / 410558, filed October 20, 2016, the content of which is hereby incorporated by reference herein in its entirety.SEQUENCE LISTING
[0002] The present specification makes reference to a Sequence Listing (submitted electronically as a .txt file named "0342941_0630_SL.TXT"). The .txt file was generated on October 13, 2017, and is 34,305 bytes in size. The entire contents of the Sequence Listing are herein incorporated by reference.TECHNICAL FIELD
[0003] The technology described herein relates to methods and compositions for determining the activity of neurotoxins, e.g., botulinum toxin.BACKGROUND
[0004] Botulinum neurotoxin (BoNT) is an agent of interest both for bioterrorism concerns as well as therapeutic applications. Traditionally, detection and characterization of BoNT has been performed by administering samples to mice, causing their death at significant doses. Assays which can be performed with cells or in vitro have been explored, but suffer from a lack of sensitivity or specificity, often causing positive signals as a result of reactions with common components of clinical samples.SUMMARY
[0005] Described herein are new assays developed to detect and measure the activity of BoNTs both in vitro and in vivo. The assays use unique single chain polypeptides that feature, e.g., a split luciferase linked through substrates of BoNTs engineered to serve as a sensor for BoNT activity. In the presence of BoNT, the linker region is cleaved by the toxin resulting in a decrease in luciferase activity, which is readily detected.
[0006] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising, from N-terminal to C-terminal: a) an N-terminal fragment of a reporter protein; b) a linker comprising a neurotoxin cleavage site; and c) a C-terminal fragment of the reporter protein; wherein the N-terminal and C-terminal fragments collectively comprise a functional reporter protein sequence; and wherein the linker functionally joins the N-terminal fragment and C-terminal fragment to generate a functional reporter fusion protein. In some embodiments of any of the aspects, the reporter protein is a luciferase protein.
[0007] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising: a) a N-terminal domain comprising a sequence with at least 90% sequence identity to amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi-isg); b) a linker comprising a neurotoxin cleavage site located C-terminal to the N-nanoi-i59; and c) a C-terminal domain having a sequence with at least 90% sequence identity amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nano160-i7o) located C-terminal to the linker; wherein the linker functionally joins the N-nanoi-i59 and the C-nanoi6o-i7o to generate a functional luciferase fusion protein.
[0008] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising: a) a N-terminal domain comprising a sequence having less than 10 amino acid residues substitutions, deletions, or additions relative to amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi-ug); b) a linker comprising a neurotoxin cleavage site located C-terminal to the N-nanoi-i59; and c) a C-terminal domain having a sequence having less than 3 amino acid residues substitutions, deletions, or additions relative to amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nanoi6o-i7o) located C-terminal to the linker; wherein the linker functionally joins the N-nanoi-i59 and the C-nanoi6o-i7o to generate a functional luciferase fusion protein.
[0009] In some embodiments of any of the aspects, the N-terminal domain has the sequence of amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi.isg) and the C-terminal domain has the sequence of amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nanoi6o-no)- In some embodiments of any of the aspects, the neurotoxin cleavage site is a C. botulinum neurotoxin (BoNT) and / or a Tetanus neurotoxin cleavage site.
[0010] In some embodiments of any of the aspects, the linker further comprises one or more spacers located between the BoNT cleavage site and the N-terminal fragment or domain , between the neurotoxin cleavage site and the C-terminal fragment of domain, or a combination thereof. In some embodiments of any of the aspects, the linker further comprises a binding fragment of a receptor for the BoNT and / or a tetanus neurotoxin. In some embodiments of anyof the aspects, the binding fragment is located between the N-terminal fragment or domain and the BoNT cleavage site. In some embodiments of any of the aspects, the linker further comprises a spacer located between the binding fragment and the BoNT cleavage site. In some embodiments of any of the aspects, at least one spacer is comprised of glycine and serine. In some embodiments of any of the aspects, at least one spacer is 5 to 15 amino acids. In some embodiments of any of the aspects, at least one spacer is selected from SEQ ID NOs: 4-9.
[0011] In some embodiments of any of the aspects, the BoNT is A, E, C, B, D, F or G. In some embodiments of any of the aspects, the BoNT cleavage site is from a SNARE protein. In some embodiments of any of the aspects, the SNARE protein is SNAP-25, synaptobrevin (VAMP), or syntaxin. In some embodiments of any of the aspects, the BoNT cleavage site is amino acids 141-206 of human SNAP-25b. In some embodiments of any of the aspects, the BoNT cleavage site is amino acid 35-96 of human VAMPl . In some embodiments of any of the aspects, the receptor is human SV2C. In some embodiments of any of the aspects, the binding fragment is amino acids 529-566 of human SV2C, or a sequence having at least 90% identity with amino acids 529-566 of human SV2C, or a sequence with no more than 10 amino acid residues substitutions, deletions, or additions relative to amino acids 529-566 of human SV2C.
[0012] In some embodiments of any of the aspects, the polypeptide further comprises a polyhistidine affinity tag. In some embodiments of any of the aspects, the polyhistidine affinity tag is located at the C-terminus of the polypeptide.
[0013] In some embodiments of any of the aspects, the linker further comprises an intact second luciferase polypeptide located between the N-terminal fragment or domain and the BoNT cleavage site. In some embodiments of any of the aspects, the second luciferase polypeptide is firefly luciferase (e.g., Photinus pyralis), bacterial luciferase (e.g., Vibrio fischeri, Vibrio harveyi), sea pansy luciferase (Renilla reniformis), dinoflagellate luciferase, Gaussia luciferase, or copepod luciferase. In some embodiments of any of the aspects, the linker further comprises a spacer located between the second luciferase polypeptide and the BoNT cleavage site. In some embodiments of any of the aspects, the spacer is from 5 to 15 amino acids. In some embodiments of any of the aspects, the spacer is GSSGGGGSGGGGSSG (SEQ ID NO: 4), GSSGGGGSGGGSSG (SEQ ID NO: 5), or GGGGS (SEQ ID NO: 6).
[0014] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising: a) amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi.i59);b) a linker located C-terminal to the N-nanoi-isg comprising: i) a first spacer of 5 to 15 amino acids; ii) a binding fragment comprised of amino acids 529-566 of SV2C located C-terminal to the first spacer; iii) a second spacer located C-terminal to the binding fragment; iv) a BoNT cleavage site comprising amino acids 141-206 of human SNAP25b located C-terminal to the second spacer; v) a third spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site; and c) amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nanoi6o-i7o) located C-terminal to the linker; wherein the linker functionally joins the N-nanoi.159 and the C-nanoieo-no to generate a functional luciferase fusion protein.
[0015] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising: a) amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi.i59); b) a linker located C-terminal to the N-nanoi-i59 comprising: i) a first spacer from 5 to 15 amino acids; ii) a BoNT cleavage site comprising amino acids 141-206 of human SNAP25b located C-terminal to the first spacer; iii) a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site; and c) amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nanoi6o-ivo) located C-terminal to the linker; wherein the linker functionally joins the N-nanoi.i59 and the C-nanoi6o-no to generate a functional luciferase fusion protein.
[0016] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising: a) amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi-159); b) a linker located C-terminal to the N-nanoi.i59 comprising: i) a first spacer of 5 to 15 amino acids; ii) a BoNT cleavage site comprising amino acids 35-96 of human VAMP1 located C-terminal to the first spacer; iii) a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site; and c) amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nanoi6o-i7o) located C-terminal to the linker; wherein the linker functionally joins the N-nanoi.isg and the C-nanoi6o-i7o to generate a functional luciferase fusion protein.
[0017] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising: a) amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi.159); b) a linker located C-terminal to the N-nanoi.isg comprising: i) a second functional luciferase polypeptide; ii) a first spacer of 5 to 15 amino acids located C-terminal of the second luciferase polypeptide; iii) a BoNT cleavage site comprising amino acids 1-206 of human SNAP25b located C-terminal to the first spacer; iv) a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site; and c) amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nanoi6o-no) located C-terminal to the linker; wherein the linker functionally joins the N-nanoi.159 and the C-nanoi6o-i7o to generate a functional luciferase fusion protein.
[0018] In some embodiments of any of the aspects, one or more spacers areGS S GGGGS GGGGS S G (SEQ ID NO: 4), GSSGGGGSGGGSSG (SEQ ID NO: 5), or GGGGS(SEQ ID NO: 6). In some embodiments of any of the aspects, the polypeptide further comprises a His6 sequence (SEQ ID NO: 12) located at the C-terminus.
[0019] In one aspect of any of the embodiments, described herein is a nucleic acid comprising a nucleotide sequence that encodes a single chain polypeptide described herein. In one aspect of any of the embodiments, described herein is a nucleic acid vector comprising a nucleic acid comprising a nucleotide sequence that encodes a single chain polypeptide described herein. In some embodiments of any of the aspects, the vector is an expression vector and comprises the nucleic acid sequence in expressible form. In some embodiments of any of the aspects, the vector is selected from the group consisting of a viral expression vector, a prokaryotic expression vector, a yeast expression vector, an insect expression vector, or a mammalian expression vector.
[0020] In one aspect of any of the embodiments, described herein is a cell comprising a nucleic acid or vector of the foregoing paragraph. In some embodiments of any of the aspects, the cell expresses a single chain polypeptide as described herein. In some embodiments of any of the aspects, the cell is a prokaryotic cell, a yeast cell, an insect cell, or an animal cell.
[0021] In one aspect of any of the embodiments, described herein is a method for determining the potency of a botulinum neurotoxin, comprising: contacting the neurotoxin to a single chain polypeptide as described herein under conditions appropriate for BoNT activity; and determining the luciferase activity of the polypeptide, as compared to a reference, thereby determining the potency.
[0022] In one aspect of any of the embodiments, described herein is amethod for detecting C. botulinum neurotoxin (BoNT) activity in a sample, comprising: contacting the sample to a single chain polypeptide as described herein under conditions appropriate for BoNT activity; and determining luciferase activity of the polypeptide, as compared to luciferase activity of the polypeptide in the absence of the sample, wherein a decrease of luciferase activity indicates BoNT activity in the sample.
[0023] In some embodiments of any of the aspects, the method is performed in vitro. In some embodiments of any of the aspects, contacting occurs in a buffer of 50mM HEPES, 20 μΜ ZnCl2, 2 mM DTT, 1 mg / ml BSA, pH 7.1. In some embodiments of any of the aspects, the concentration of the single chain polypeptide contacted to the sample is from about 30 nM to 300 nM. In some embodiments of any of the aspects, the concentration of single chain polypeptide contacted to the sample is about 30 nM.
[0024] In some embodiments of any of the aspects, the luciferase activity is determined by addition of luciferase substrate to the single chain polypeptide and quantitative measurement of a luminescent signal produced. In some embodiments of any of the aspects, the conditions comprise incubation at about 37°C for a period of from about 1 hour to about 36 hours. In some embodiments of any of the aspects, the conditions comprise incubation at about 37°C for a period of from about 1 hour to about 24 hours. In some embodiments of any of the aspects, the conditions comprise incubation at about 37°C for a period of from about 4 hours to about 24 hours.
[0025] In some embodiments of any of the aspects, the linker comprises a first spacer of 5 to 15 amino acids, a binding fragment of amino acids 529-566 of human SV2C located C-terminal to the first spacer and N-terminal to the BoNT cleavage site, and a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site, wherein the BoNT cleavage site comprises amino acids 141-206 of human SNAP25. In some embodiments of any of the aspects, the linker comprises a first spacer of 5 to 15 amino acids located N-terminal to the BoNT cleavage site, and a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site, wherein the BoNT cleavage site comprises amino acids 141-206 of human SNAP25. In some embodiments of any of the aspects, the linker comprises a first spacer of 5 to 15 amino acids located N-terminal to the BoNT cleavage site, a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site, wherein the BoNT cleavage site comprises amino acids 35-96 of human VAMPl .
[0026] In some embodiments of any of the aspects, the single chain polypeptide is expressed by a neuronal cell and the method further comprises, after the contacting step: incubating the neuronal cells for a period of from about 12 hours to about 60 hours and harvesting lysate from the neuronal cells.
[0027] In one aspect of any of the embodiments, described herein is a method for detecting C. botulinum neurotoxin (BoNT) activity in a sample, comprising: a) contacting the sample to neuronal cells expressing a single chain polypeptide comprising: amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi.139), amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nanoi6o-no), separated and functionally joined by a linker comprising a BoNT cleavage site located C-terminal to the N-nanoi-159 and N-terminal to the C-nanoi6o-i7o ; b) incubating the neuronal cells for a period of from about 12 hours to about 60 hours; c) harvesting lysate from the neuronal cells; and d) measuring luciferase activity in the lysate, as compared to luciferase activity in identically treated neuronal cells in the absence of the sample, wherein a decrease in the luciferase activity indicates BoNT activity in the sample.
[0028] In some embodiments of any of the aspects, the linker further comprises an intact second luciferase polypeptide located between the N-nanoi-i59 and the cleavage site. In some embodiments of any of the aspects, the second luciferase polypeptide firefly luciferase (photinus pyralis), bacterial luciferase (vibrio fischiri, vibrio harveyi), sea pansy luciferase (renilla reniformis), dinoflagellate luciferase, gaussia luciferase, or copepod luciferase. In some embodiments of any of the aspects, the luciferase activity of the second luciferase polypeptide in the sample is determined and used as an indicator of total single chain polypeptide present in the harvested lysate. In some embodiments of any of the aspects, the neuronal cells express the single chain polypeptide from a viral expression vector. In some embodiments of any of the aspects, the single chain polypeptide is expressed for 6 days prior to step a). In someembodiments of any of the aspects, the viral expression system is a lentivirus expression system.
[0029] In some embodiments of any of the aspects, the incubating step is about 48 hours. In some embodiments of any of the aspects, the harvesting step is by addition of a lysis buffer.
[0030] In some embodiments of any of the aspects, the BoNT cleavage site is from SNAP-25, synaptobrevin (VAMP), or syntaxin. In some embodiments of any of the aspects, the BoNT cleavage site is specifically recognized by BoNT A, E and C, or is specifically recognized by BoNT B, D, F and G. In some embodiments of any of the aspects, a combination of single chain polypeptides having different BoNT cleavage sites are used. In some embodiments of any of the aspects, the BoNT cleavage site is a.a.141-206 of human SNAP-25, or a. a. 35-96 of human VAMPl, a.a. 1-206 of human SNAP35, or a.a. 1-96 of VAMPl . In some embodiments of any of the aspects, the linker further comprises a binding fragment of a BoNT receptor. In someembodiments of any of the aspects, the receptor is SV2C. In some embodiments of any of the aspects, the binding fragment comprises amino acids 529-566 of human SV2C.
[0031] In some embodiments of any of the aspects, the linker comprises a second luciferase polypeptide, a first spacer of 5 to 15 amino acids located C-terminal of the second luciferase polypeptide and N-terminal of the BoNT cleavage site, a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site, wherein the BoNT cleavage site comprises amino acid 1-206 of human SNAP25 and is located C-terminal to the first spacer.
[0032] In some embodiments of any of the aspects, the measurement of luciferase activity is accomplished by addition of a substrate specific for the luciferase and quantitative detection of the resulting luminescent signal. In some embodiments of any of the aspects, the substrate for the luciferase of SEQ ID NO: 1 is furimazine (2-furanylmethyl-deoxy-coelenterazine).
[0033] In one aspect, described herein is a kit comprising: a) one or more single chain polypeptides as described herein, with each or a combination of the single chain polypeptides packaged into a separate container; b) one or more nucleic acids or nucleic acid vectors as described herein, with each or a combination of the nucleic acids or nucleic acid vectors packaged into a separate container; and / or c) one or more cells as described herein with each or a combination of the cells packaged into a separate container. In some embodiments of any of the aspects, the kit further comprises a luciferase substrate packaged into a separate container.BRIEF DESCRIPTION OF THE DRAWINGS
[0034] FIG. 1 depicts a schematic drawing of split luciferase based toxin sensors. Left panel: NANOLUC™ luciferase is separated into two complementary fragments, N-nano and C-nano. These two fragments are linked together with a linker that is based on toxin substrates (SNAP -25 (also known as p25) or VAMP1 / 2 / 3 (e.g., synaptobrevins)). Right panel: Cleavage of the linker region by BoNTs separates the two parts of NANOLUC™ luciferase and abolishes the luminescent signals.
[0035] FIG. 2A-FIG. 2B demonstrate an in vitro detection assay of BoNT / A. Two sensor proteins were designed and investigated for BoNT / A toxin detection. One is NNano-SV2C-L4-p25-CNano whereas the other one is NNano-p25-C ano They were prepared at 30 nM in 30 ul volume while the BoNT / A was diluted from 1 nM to 1 fJVI with factor 10. The negative control was BoNT / B added in the sensor protein solution. The curve (FIG. 2A) was plotted based on the percentage of luminescence of NANOLUC™ luciferase. EC50 of using NNano-SV2C-p25-CNanofor BoNT / A is 9.73 pM after 4h and 7.86 pM after 24h, meanwhile EC50 of using NNano-p25-CNaiio is 48.26 pM after 4h and 35.87 pM after 24h at 37°C. The sensor protein containing SV2C-L4 which is BoNT / A binding domain showed approximate 5-fold increase of EC50 (FIG. 2B).
[0036] FIG. 3A-FIG. 3B demonstrate an in vitro detection assay of BoNT / B after 4h and 24h. The sensor protein N ano- AMPl-CNano was prepared at 30 nM in 30 ul volume while the BoNT / B was diluted from 10 nM to 1 fJVI with factor 10. The negative control was BoNT / A added in the sensor protein solution. The curve (FIG. 3A) was plotted based on the percentage of luminescence of NANOLUC™ luciferase. EC 50 for BoNT / B is 75.7 pM after 4h and 3.9 pM after 24h at 37°C (FIG. 3B).
[0037] FIG. 4 demonstrates an in vivo detection assay of BoNT / A using virus infected neurons cells. For each neuron cell lysate sample, both Firefly and NANOLUC™ luciferase signals were measured and the ratio (NANOLUC™ / Firefly) was calculated. Afterwards, the percentage of each sample's ratio was generated using no toxin exposure as reference control. The EC50= 2.9 pM equal to 30 fold of LD50 after 48h challenged with toxin proteins.DETAILED DESCRIPTION
[0038] Described herein are compositions and methods relating to measuring and / or detecting enzymatic activity. In particular, the compositions and methods relate to the detection and / or measurement of neurotoxins, e.g., C. botulinum neurotoxin (BoNT).
[0039] As used herein, "C. botulinum neurotoxin" or "BoNT" refers to any polypeptide that can execute the overall cellular mechanism whereby a C. botulinum toxin enters a neuron and inhibits neurotransmitter release and encompasses the binding of a C. botulinum toxin to a low or high affinity receptor complex, the internalization of the toxin, the translocation of the toxin light chain into the cytoplasm and the enzymatic modification of a C. botulinum toxin substrate.
[0040] Strains of Clostridium botulinum produce seven antigenically-distinct types of Botulinum toxins (BoNTs), which have been identified by investigating botulism outbreaks in man (BoNT / A, / B, IE and / F), animals (BoNT / Cl and / D), or isolation from soil (BoNT / G). While all seven BoNT serotypes have similar structure and pharmacological properties, each also displays heterogeneous bacteriological characteristics. The genetic diversity of the C. botulinum strains is described in detail in Hill et al. (Journal of Bacteriology, Vol. 189, No. 3, p. 818-832 (2007)), the contents of which are incorporated herein by reference. In some embodiments ofany of the aspects described herein, the BoNT is of strain A, E, C, B, D, F or G. Various non-naturally occurring C. botulinum neurotoxins are also known in the art and described, e.g., in International Patent Publications W095 / 32738, W096 / 33273, WO98 / 07864 and WO99 / 17806, each of which is incorporated herein by reference.
[0041] Toxins from the various C. botulinum strains share the same functional domain organization and overall structural architecture. C. botulinum toxins are each translated as a single chain polypeptide of approximately 150 kDa that is subsequently cleaved by proteolytic scission within a disulfide loop by a naturally-occurring proteases, such as, e.g., an endogenous C. botulinum toxin protease or a naturally-occurring proteases produced in the environment. This posttranslational processing yields a di-chain molecule comprising an approximately 50 kDa light chain (LC) and an approximately 100 kDa heavy chain (HC) held together by a single disulfide bond and noncovalent interactions. Each mature di-chain molecule comprises three functionally distinct domains: 1) a proteolytic domain located in the LC that includes a metalloprotease region containing a zinc-dependent endopeptidase activity which specifically targets core components of the neurotransmitter release apparatus; 2) a translocation domain contained within the amino-terminal half of the HC (HN) that facilitates release of the LC from intracellular vesicles into the cytoplasm of the target cell; and 3) a binding domain found within the carboxyl -terminal half of the HC that determines the binding activity and binding specificity of the toxin to the receptor complex located at the surface of the target cell.
[0042] The binding, translocation and protease activity of these three functional domains are all necessary for toxicity. The overall cellular intoxication mechanism whereby C. botulinum toxins enter a neuron and inhibit neurotransmitter release is similar, regardless of serotype or subtype. Without wishing to be bound by theory, the intoxication mechanism involves at least four steps: 1) receptor binding, 2) complex internalization, 3) light chain translocation, and 4) protease target modification. The process is initiated when the He domain of a C. botulinum toxin binds to a toxin-specific receptor located on the plasma membrane surface of a target cell. The binding specificity of a receptor complex is thought to be achieved, in part, by specific combinations of gangliosides and protein receptors. Once bound, the toxin / receptor complexes are internalized by endocytosis and the internalized vesicles are sorted to specific intracellular routes. The translocation step is triggered by the acidification of the vesicle compartment. Once translocated, light chain endopeptidase of the toxin is released from the intracellular vesicle into the cytosol where it specifically targets one of three proteins known as the core components of the neurotransmitter release apparatus (vesicle-associated membrane protein(VAMP) / synaptobrevin, synaptosomal-associated protein of 25 kDa (SNAP-25) and Syntaxin).
[0043] These core components are necessary for synaptic vesicle docking and fusion at the nerve terminal and constitute members of the soluble N-ethylmaleimide-sensitive factor-attachment protein-receptor (SNARE) family. BoNT / A and BoNT / E cleave SNAP-25 in the carboxyl-terminal region, releasing a nine or twenty-six amino acid segment, respectively, and BoNT / Cl also cleaves SNAP-25 near the carboxyl-terminus. The botulinum serotypes BoNT B, BoNT / D, BoNT / F and BoNT / G, and tetanus toxin, act on the conserved central portion of VAMP, and release the amino-terminal portion of VAMP into the cytosol. BoNT / Cl cleaves syntaxin at a single site near the cytosolic plasma membrane surface. The selective proteolysis of synaptic SNAREs accounts for the block of neurotransmitter release caused by C. botulinum toxins in vivo. The SNARE protein targets of C. botulinum toxins are common to exocytosis in a variety of non-neuronal types; in these cells, as in neurons, light chain peptidase activity inhibits exocytosis, see, e.g., Yann Humeau et al., How Botulinum and Tetanus Neurotoxins Block Neurotransmitter Release, 82(5) Biochimie. 427-446 (2000); Kathryn Turton et al., Botulinum and Tetanus Neurotoxins: Structure, Function and Therapeutic Utility, 27(11) Trends Biochem. Sci. 552-558. (2002); Giovanna Lalli et al., The Journey of Tetanus and Botulinum Neurotoxins in Neurons, 11(9) Trends Microbiol. 431-437, (2003).
[0044] Described herein are single chain polypeptides in which a reporter protein is split or interrupted in its sequence by a linker segment. The split reporter protein is functional.
[0045] As used herein, the term "single chain" when referring to a polypeptide refers to a single polypeptide molecule having a series of amino acid residues, connected to each other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues. That is, each recited element of a single chain polypeptide is connected to the other element(s) by means of a peptide bond. This is in contrast to multi-chain polypeptides which comprise multiple single chain polypeptides which can bind to each other via, e.g., hydrogen bonding or disulfide bonds to form a polypeptide complex.
[0046] The single chain polypeptides described herein can comprise luciferase and / or portions thereof, e.g., the reporter protein can be luciferase. As used herein, "luciferase" refers to an enzyme that catalyzes a bioluminescent reaction, e.g., by catalyzing the oxidation ofluciferin, emitting light and releasing oxyluciferin. A luciferase can be naturally-occurring or engineered. As used herein, a "functional" luciferase is a luciferase that is capable of catalyzing a reaction in the presence of a suitable substrate. Numerous variations and embodiments of luciferase are available, including, e.g., firefly luciferase (Photinus pyralis) (see, e.g, SEQ ID NO: 13), bacterial luciferase (Vibrio fischeri, Vibrio harveyi), sea pansy luciferase (Renilla reniformis), dinoflagellate luciferase, Cypridina luciferase, Coleoptera luciferase, Gaussia luciferase (see, e.g., Heise, K., et al, "Dual luciferase assay for secreted luciferase based on Gaussia and NANOLUC" Assay Drug Dev. Technol.(2013); which is incorporated by reference herein in its entirety), copepod luciferase (see, e.g., Takenaka, Y., et al, "Computational analysis and functional expression of ancestral copepod luciferase" Gene (2013); which is incorporated by reference herein in its entirety) and NANOLUC™ luciferase.
[0047] In some embodiments of any of the aspects described herein, the luciferase can be NANOLUC™ luciferase. As used herein, "NANOLUC luciferase" refers to a 19.1 kDa luciferase derived from Oplophorus gracilirostris luciferase that can utilize furimazine or coelenterazine as a substrate and which has the sequence of SEQ ID NO: 1. Variants of NANOLUC™ luciferase can also be used in any of the aspects and embodiments of the methods and compositions herein and are described, e.g., in US Patent No. 8,557,970; which is incorporated by reference herein in its entirety.
[0048] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising, from N-terminal to C-terminal: a N-terminal fragment of a reporter protein; a linker comprising a neurotoxin cleavage site; and a C-terminal fragment of the reporter protein. As used herein, "fragment" refers to a part or portion of a molecule, e.g., a part or portion of a polypeptide. In the single chain polypeptides described herein, the N-terminal fragment and C-terminal fragments of a reporter protein collectively comprise a functional reporter protein sequence but do not individually comprise a functional reporter protein sequence. When present in the same single chain polypeptide, e.g., joined functionally by the linker sequence, the N-terminal and C-terminal fragments of a reporter protein generate a functional reporter fusion protein. In some embodiments of any of the aspects, the reporter protein is a luciferase protein. In some embodiments of any of the aspects, the fragments can be variants or derivatives of naturally-occurring sequences, reporter protein sequences described herein, and / or reporter protein sequences known in the art, e.g., they can have at least 90%sequence identity to a reporter protein sequence or have no more than 10 amino acid residue substitutions, deletions, or additions relative to a reporter protein sequence.
[0049] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising a N-terminal domain comprising a sequence with at least 90% sequence identity to amino acids 1-159 of the luciferase of SEQ ID NO 1 (N-nano 1.159); a linker comprising a neurotoxin cleavage site located C-terminal to the N-nanoi.159; and a C-terminal domain having a sequence with at least 90% sequence identity amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nano^o-no) located C-terminal to the linker; wherein the linker functionally joins the N-nanoi-i59 and the C-nano^o-no to generate a functional luciferase fusion protein.
[0050] In some embodiments of any of the aspects, a domain or fragment of a reporter protein can have at least at least 90%, at least 95%, or at least 98% sequence identity with a reporter protein sequence, e.g., with amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi-159) or amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nanoi6o-i7o). In some embodiments of any of the aspects, the variant amino acids can be conservative substitution variations.
[0051] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising: a N-terminal domain comprising a sequence having less than 10 amino acid residues substitutions, deletions, or additions relative to amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nano 1.159); a linker comprising a neurotoxin cleavage site located C-terminal to the N-nanoi-159; and a C-terminal domain having a sequence having less than 3 amino acid residues substitutions, deletions, or additions relative to amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nano^o-no) located C-terminal to the linker; wherein the linker functionally joins the N-nanoi-159 and the C-nano^o-no to generate a functional luciferase fusion protein.
[0052] In some embodiments of any of the aspects, a domain or fragment of a reporter protein can be a sequence with 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 deletions, insertions, or substitutions relative to a reporter protein sequence, e.g., to amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi-i59) or amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nano^o-no)- In some embodiments of any of the aspects, the substituted amino acids can be conservative substitution variations. In oneaspect of any of the embodiments, described herein is a single chain polypeptide comprising: a) amino acids 1-159 of NANOLUC™ luciferase (N-nanoi.isg); b) a linker comprising a neurotoxin cleavage site located C-terminal to the -nanoi.159; and c) amino acids 160-170 of NANOLUC™ luciferase (C-nanoieo-no) located C-terminal to the linker; wherein the linker functionally joins the N-nanoi-159 and the C-nano^o-no to generate a functional luciferase fusion protein.
[0053] As demonstrated herein, a luciferase protein can be interrupted by a linker sequence while still providing a functional luciferase. In some embodiments of any of the aspects described herein, a linker is provided between residues corresponding to residues 159 and 160 of SEQ ID NO: 1. In some embodiments of any of the aspects described herein, a linker is provided between residues 159 and 160 of SEQ ID NO: 1.
[0054] In some embodiments of any of the aspects described herein, a single chain polypeptide as described herein can comprise an N-terminal domain comprising a sequence corresponding to residues 1-159 of SEQ ID NO: 1 and a C-terminal domain comprising a sequence corresponding to residues 160-170 of SEQ ID NO: 1. In some embodiments of any of the aspects described herein, a single chain polypeptide as described herein can comprise an N-terminal domain consisting essentially of a sequence corresponding to residues 1-159 of SEQ ID NO: 1 and a C-terminal domain consisting essentially of a sequence corresponding to residues 160-170 of SEQ ID NO: 1.
[0055] In some embodiments of any of the aspects described herein, a single chain polypeptide as described herein can comprise an N-terminal domain comprising residues 1-159 of SEQ ID NO: 1 and a C-terminal domain comprising residues 160-170 of SEQ ID NO: 1. In some embodiments of any of the aspects described herein, a single chain polypeptide as described herein can comprise an N-terminal domain consisting essentially of residues 1-159 of SEQ ID NO: 1 and a C-terminal domain consisting essentially of residues 160-170 of SEQ ID NO: 1. In some embodiments of any of the aspects described herein, a single chain polypeptide as described herein can comprise an N-terminal domain consisting of residues 1-159 of SEQ ID NO: 1 and a C-terminal domain consisting of residues 160-170 of SEQ ID NO: 1.
[0056] In the single chain polypeptides described herein, a linker domain is found between the N-terminal and C-terminal domains. As used herein, "linker" refers to a sequence exogenous to a reporter protein (e.g. a luciferase enzyme) and which is engineered to functionally join the N-terminal and C-terminal domains of the reporter protein. A linker can comprise, e.g., one or more cleavage sites, one or more spacers, one or more binding fragments, and one or more additional luciferase enzymes.
[0057] As used herein, "functionally join" refers to joining the two fragments of a reporter protein, e.g., a luciferase in such a way that the intervening sequence does not prevent the two fragments from forming an active and functional tertiary structure. Two fragments which are functionally joined will exhibit the activity which characterizes the protein in the absence of the linker sequence.
[0058] In some embodiments of any of the aspects described herein, a linker can comprise one or more cleavage sites, e.g., an amino acid sequence which is specifically cleaved by the action of one or more enzymes. In some embodiments of any of the aspects described herein, the cleavage site can be a neurotoxin cleavage site. Accordingly, a neurotoxin cleavage site comprises a sequence which is specifically cleaved by at least one neurotoxin. Neurotoxins are compounds which inhibit the function of and / or kill nervous tissue. In some embodiments of any of the aspects described herein, the neurotoxin can be an inhibitor of synaptic vesicle release. Exemplary non-limiting neurotoxin cleavage sites can include a C. botulinum neurotoxin (BoNT) and / or a Tetanus neurotoxin cleavage site. In some embodiments of any of the aspects described herein, a linker can comprise multiple neurotoxin cleavage sites, e.g., it can be cleaved by multiple neurotoxins, thereby permitting the detection and / or measurement of multiple neurotoxins.
[0059] BoNT acts by cleaving SNARE proteins. Accordingly, a BoNT cleavage site can be from a SNARE protein. As used herein, "SNARE protein" refers to a superfamily of proteins that mediate vesicle fusion, including fusion of synaptic vesicles of the presynaptic membrane in neurons. SNARE proteins include, by way of non-limiting examples, SNAP-25 (e.g., NCBI Gene ID: 6616, see also NCBI Reference Sequence: NP_570824.1 for human SNAP25b and NCBI Reference Sequence: NP_112253.1 for rat SNAP25b), synaptobrevins (VAMPs)(e.g., NCBI Gene ID Nos: 6843; 6844; 6845; 8673; 8674; 9341; 9554; 10652; 10791 ; and 26984) and syntaxins (e.g., NCBI Gene ID Nos. 2054; 6804; 6809; 6810; 6811 ; 8417; 8675; 8676; 8677; 9482; 10228; 23673; 53407; 55014; 112755; and 415177). SNARE scissile bonds cleaved by clostridial neurotoxins are described for example in Binz, Th. et al. "Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering."Toxins 2.4 (2010): 665-682. Preferably, the BoNT cleavage site is from a human SNARE protein. Examples of human SNARE scissile bonds are provided in Table 1.
[0060] Table 1 - human SNARE scissile bonds cleaved by clostridial neurotoxinsNeurotoxin SNARE Scissile bondBoNT / A SNAP25 (SEQ ID NO: 23) Glnl97-Argl98BoNT / B VAMP-1 (SEQ ID NO:24). Gln78-Phe79VAMP-2 (SEQ ID NO:25). Gln76-Phe77VAMP-3 (SEQ ID NO:26). Gln59-Phe60BoNT / Cl SNAP25 (SEQ ID NO: 23). Argl98-Alal99Syntaxin 1A (SEQ ID NO: 27). Lys253-Ala254Syntaxin IB (SEQ ID NO: 28). Lys252-Ala253BoNT / D VAMP-1 (SEQ ID NO:24). Lys61 -Leu62VAMP-2 (SEQ ID NO: 25). Lys59-Leu60VAMP-3 (SEQ ID NO: 26). Lys42-Leu43Bridge / E SNAP25 (seq ID NO: 23). Argl 80-Ilel 81BoNT / F VAMP-1 (SEQ ID NO: 24). Gln60-Lys61VAMP-2 (SEQ ID NO: 25). Gln58-Lys59VAMP-3 (SEQ ID NO: 26). Gln41-Lys42BoNT / G VAMP-1 (SEQ ID NO: 24). Ala83-Ala84VAMP-2 (SEQ ID NO: 25). Ala81-Ala82VAMP-3 (SEQ ID NO: 26). Ala64-Ala65TeNT VAMP-1 (SEQ ID NO: 24). Gln78-Phe79VAMP-2 (SEQ ID NO: 25) Gln76-Phe77VAMP-3 (SEQ ID NO: 26). Gln59-Phe60
[0061] In one embodiment, the linker comprises at least one clostridial neurotoxin cleavage site, preferably a human neurotoxin cleavage site. A clostridial neurotoxin cleavage site may be defined as a sequence comprising at least amino acid residues Ρ3Ρ2Ρ1Ρ Ρ2'Ρ3' of a SNARE, preferably a human SNARE, wherein PI and PI ' are the residues located on either side of the scissile peptide bond cleaved by the clostridial neurotoxin, for example Glnl97 and Argl98 in human SNAP25 for BoNT / A.
[0062] In a preferred embodiment, a clostridial neurotoxin cleavage site comprises at least amino acid residues P4P3P2P1P1 'P2'P3'P4' of the SNARE. In a more preferred embodiment, a clostridial neurotoxin cleavage site comprises at least amino acid residuesP5P4P3P2P1P1 'P2'P3'P4'P5' of the SNARE, more preferably at least amino acid residues P6P5P4P3P2P1P1 'P2'P3 'P4'P5'P6'.
[0063] In one embodiment, the linker comprises at least one BoNT / A cleavage site wherein said BoNT / A cleavage site comprises residues 195 to 200, preferably 194 to 201, 193 to 202 or192 to 203 of human SNAP25 (SEQ ID NO: 23).
[0064] In one embodiment, the linker comprises at least one BoNT / B cleavage site wherein said BoNT / B cleavage site comprises residues 76 to 81, preferably 75 to 82, 74 to 83 or 73 to 84 of human VAMP-1 (SEQ ID NO: 24).
[0065] In one embodiment, the linker comprises at least one BoNT / B cleavage site wherein said BoNT / B cleavage site comprises residues 74 to 79, preferably 73 to 80, 72 to 81 or 71 to 82 of human VAMP-2 (SEQ ID NO: 25).
[0066] In one embodiment, the linker comprises at least one BoNT / B cleavage site wherein said BoNT / B cleavage site comprises residues 57 to 62, preferably 56 to 63, 55 to 64 or 54 to 65 of human VAMP-3 (SEQ ID NO: 26).
[0067] In one embodiment, the linker comprises at least one BoNT / C l cleavage site wherein said BoNT / Cl cleavage site comprises residues 196 to 201, preferably 195 to 202, 194 to 203 or193 to 204 of human SNAP25 (SEQ ID NO: 23).
[0068] In one embodiment, the linker comprises at least one BoNT / C l cleavage site wherein said BoNT / Cl cleavage site comprises residues 251 to 256, preferably 250 to 257, 249 to 258 or148 to 259 of human Syntaxin 1A(SEQ ID NO: 27).
[0069] In one embodiment, the linker comprises at least one BoNT / C l cleavage site wherein said BoNT / Cl cleavage site comprises residues 252 to 257, preferably 251 to 258, 249 to 259 or149 to 260 of human Syntaxin IB (SEQ ID NO: 28).
[0070] In one embodiment, the linker comprises at least one BoNT / D cleavage site wherein said BoNT / D cleavage site comprises residues 59 to 64, preferably 58 to 65, 57 to 66 or 56 to 67 of human VAMP-1 (SEQ ID NO: 24).
[0071] In one embodiment, the linker comprises at least one BoNT / D cleavage site wherein said BoNT / D cleavage site comprises residues 57 to 62, preferably 56 to 63, 55 to 64 or 54 to 65 of human VAMP-2 (SEQ ID NO: 25).
[0072] In one embodiment, the linker comprises at least one BoNT / D cleavage site wherein said BoNT / D cleavage site comprises residues 40 to 45, preferably 39 to 46, 38 to 47 or 37 to 48 of human VAMP-3 (SEQ ID NO: 26).
[0073] In one embodiment, the linker comprises at least one BoNT / E cleavage site wherein said BoNT / E cleavage site comprises residues 178 to 183, preferably 177 to 184, 176 to 185 or 175 to 186 of human SNAP25 (SEQ ID NO: 23).
[0074] In one embodiment, the linker comprises at least one BoNT / F cleavage site wherein said BoNT / F cleavage site comprises residues 58 to 63, preferably 57 to 64, 56 to 65 or 55 to 66 of human VAMP-1 (SEQ ID NO: 24).
[0075] In one embodiment, the linker comprises at least one BoNT / F cleavage site wherein said BoNT / F cleavage site comprises residues 56 to 61, preferably 55 to 62, 54 to 63 or 53 to 64 of human VAMP-2 (SEQ ID NO: 25).
[0076] In one embodiment, the linker comprises at least one BoNT / F cleavage site wherein said BoNT / F cleavage site comprises residues 39 to 44, preferably 38 to 45, 37 to 46 or 36 to 47 of human VAMP-3 (SEQ ID NO: 26).
[0077] In one embodiment, the linker comprises at least one BoNT / G cleavage site wherein said BoNT / G cleavage site comprises residues 81 to 86, preferably 80 to 87, 79 to 88 or 78 to 89 of human VAMP-1 (SEQ ID NO: 24).
[0078] In one embodiment, the linker comprises at least one BoNT / G cleavage site wherein said BoNT / G cleavage site comprises residues 79 to 84, preferably 78 to 85, 77 to 86 or 76 to 87 of human VAMP-2 (SEQ ID NO: 25).
[0079] In one embodiment, the linker comprises at least one BoNT / G cleavage site wherein said BoNT / G cleavage site comprises residues 62 to 67, preferably 61 to 68, 60 to 69 or 59 to 70 of human VAMP-3 (SEQ ID NO: 26).
[0080] In one embodiment, the linker comprises at least one BoNT / B cleavage site wherein said TeNT cleavage site comprises residues 76 to 81, preferably 75 to 82, 74 to 83 or 73 to 84 of human VAMP-1 (SEQ ID NO: 24).
[0081] In one embodiment, the linker comprises at least one TeNT cleavage site wherein said TeNT cleavage site comprises residues 74 to 79, preferably 73 to 80, 72 to 81 or 71 to 82 of human VAMP-2 (SEQ ID NO: 25).
[0082] In one embodiment, the linker comprises at least one TeNT cleavage site wherein said BoNT / B cleavage site comprises residues 57 to 62, preferably 56 to 63, 55 to 64 or 54 to 65 of human VAMP-3 (SEQ ID NO: 26).
[0083] An example of suitable BoNT cleavage sites in SNARE proteins include, by way of non-limiting example, amino acids 141-206 of human SNAP-25b (e.g., SEQ ID NO: 10); and amino acid 35-96 of human VAMP1 (e.g., NCBI Gene ID: 6843). In some embodiments of any of the aspects described herein, amino acids of 35-96 of human VAMP1 can be amino acids 35-96 of SEQ ID NO: 16. Further non-limiting examples of BoNT cleavage sites in SNARE proteins include amino acids 60-87 of human VAMP2, amino acids 43-70 of human VAMP 3, and amino acids 62-89 of human VAMP1. In some embodiments of any of the aspects, amino acids 60-87 of human VAMP2 can be the sequence of SEQ ID NO: 19. In some embodiments of any of the aspects, amino acids 43-70 of human VAMP3 can be the sequence of SEQ ID NO: 20. In some embodiments of any of the aspects, amino acids 62-89 of human VAMP1 can be the sequence of SEQ ID NO: 21
[0084] In some embodiments of any of the aspects, a BoNT cleavage site can be a variant of any of the specific sequences recited herein, e.g., a variant of a native BoNT cleavage site found in a SNARE protein. In some embodiments of any of the aspects, a BoNT cleavage site can be a variant of amino acids 141-206 of SEQ ID NO: 10 or amino acids 35-96 of SEQ ID NO: 16. In some embodiments of any of the aspects, a BoNT cleavage site can have at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity with a native BoNT cleavage site found in a SNARE protein In some embodiments of any of the aspects, a BoNT cleavage site can have at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity with amino acids 141-206 of SEQ ID NO: 10 or amino acids 35-96 of SEQ ID NO: 16. In some embodiments of any of the aspects, the variant can be a conservative substitution variant.
[0085] In some embodiments of any of the aspects, a BoNT cleavage site can be a sequence with 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 deletions, insertions, or substitutions relative to a native BoNT cleavage site found in a SNAREprotein. In some embodiments of any of the aspects, a BoNT cleavage site can be a sequence with 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 residues which vary relative to a native BoNT cleavage site found in a SNARE protein. In some embodiments of any of the aspects, a BoNT cleavage site can be a sequence with 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 deletion, insertion, or substitution relative to amino acids 141-206 of SEQ ID NO: 10 or amino acids 35-96 of SEQ ID NO: 16. In some embodiments of any of the aspects, a BoNT cleavage site can be a sequence with 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 residues which vary relative to with amino acids 141-206 of SEQ ID NO: 10 or amino acids 35-96 of SEQ ID NO: 16.
[0086] In some embodiments of any of the aspects described herein, a BoNT cleavage site can comprise amino acids 141-206 of human SNAP-25b (e.g., SEQ ID NO: 10); amino acid 35-96 of human VAMPl; amino acids 1-96 of VAMPl ; human SNAP25; and / or amino acids 1-206 of human SNAP25b (SEQ ID NO: 14).
[0087] In some embodiments of any of the aspects described herein, a BoNT cleavage site can be specifically recognized (e.g. cleaved) by BoNT A, B, C, D, E, F, and / or G. In some embodiments of any of the aspects described herein, a BoNT cleavage site can be specifically recognized (e.g. cleaved) by BoNT A, E and C. In some embodiments of any of the aspects described herein, a BoNT cleavage site can be specifically recognized (e.g. cleaved) by BoNT B, D, F and G.
[0088] In some embodiments of any of the aspects described herein, a linker can comprise one or more spacers. As used herein, "spacer" refers to an amino acid sequence that serves the structural purpose of separating two other sequences in the same peptide chain. In some embodiments of any of the aspects described herein, the spacer sequence can be a flexible peptide sequence. In some embodiments of any of the aspects described herein, a spacer can comprise glycine and serine residues. In some embodiments of any of the aspects described herein, a spacer can consist essentially of glycine and serine residues. In some embodiments of any of the aspects described herein, a spacer can consist of glycine and serine residues.
[0089] In some embodiments of any of the aspects described herein, a spacer can be from about 2 to about 30 amino acids in length. In some embodiments of any of the aspects described herein, a spacer can be from 2 to 30 amino acids in length. In some embodiments of any of theaspects described herein, a spacer can be from about 3 to about 20 amino acids in length. In some embodiments of any of the aspects described herein, a spacer can be from 3 to 20 amino acids in length. In some embodiments of any of the aspects described herein, a spacer can be from about 5 to about 15 amino acids in length. In some embodiments of any of the aspects described herein, a spacer can be from 5 to 15 amino acids in length.
[0090] Exemplary, non-limiting spacers can include GS S GGGGS GGGGS S G (SEQ ID NO: 4); GSSGGGGSGGGSSG (SEQ ID NO: 5); GGGGS (SEQ ID NO: 6); (GGGGS)n (n=l-3) (SEQ ID NO: 7); KESGSVSSEQLAQFRSLD (SEQ ID NO: 8); and EGKSSGSGSESKST (SEQ ID NO: 9). Linker design, selection, and further exemplary linkers are well-known in the art and described, e.g., in Chen, X., et al, "Fusion protein linkers: proterty, design and functionality" Adv. Drug Deliv. Rev. (2013); which is incorporated by reference herein in its entirety.
[0091] In some embodiments of any of the aspects described herein, a linker can comprise a neurotoxin binding fragment, e.g., a sequence that is bound by and / or binds to a neurotoxin and which is not cleaved by the neurotoxin. In some embodiments of any of the aspects described herein, a neurotoxin binding fragment can be a fragment of a neurotoxin receptor, e.g., a receptor for the BoNT and / or a tetanus neurotoxin.
[0092] In some embodiments of any of the aspects described herein, the neurotoxin receptor can be a human, mouse, rat, or primate neurotoxin receptor. In a preferred embodiment, the neurotoxin receptor is a human neurotoxin receptor. In some embodiments of any of the aspects described herein, the neurotoxin receptor can be SV2C, e.g., human SV2C (NCBI Gene ID: 22987; GenBank: AAI00828.1). In some embodiments of any of the aspects described herein, the neurotoxin binding fragment of a receptor can comprise a sequence corresponding to amino acids 529-566 of human SV2C (SV2C-L4, e.g., SEQ ID NO: 1 1). In some embodiments of any of the aspects described herein, the neurotoxin binding fragment can comprise amino acids 529-566 of human SV2C (SV2C-L4, e.g., SEQ ID NO: 11). In some embodiments of any of the aspects described herein, the neurotoxin receptor can be SYTI (NCBI Gene ID: 6857) or SYT2 (NCBI Gene ID: 127833). In some embodiments of any of the aspects described herein, the neurotoxin binding fragment of a receptor can comprise a sequence corresponding to amino acids 32-52 of SYTI (e.g., SEQ ID NO: 17) or amino acids 40-60 of SYT2 (SEQ ID NO: 18).
[0093] In some embodiments of any of the aspects described herein, a linker can comprise an intact second luciferase polypeptide. In some embodiments of any of the aspects described herein, the second luciferase is active before and / or after cleavage of the single chain polypeptide, e.g. by a neurotoxin. In some embodiments of any of the aspects described herein, the second luciferase is distinguishable from the first luciferase, e.g. it acts on a different substrate and / or produces a different wavelength of light. For example, if the first luciferase is NANOLUC, the second luciferase can be firefly luciferase (e.g., Photinus pyralis), bacterial luciferase (e.g., Vibrio fischieri, Vibrio harveyi), sea pansy luciferase (e.g., Renilla reniformis), dinoflagellate luciferase, or Gaussia luciferase. In some embodiments of any of the aspects described herein, the second luciferase can comprise a sequence corresponding to SEQ ID NO: 13. In some embodiments of any of the aspects described herein, the second luciferase can comprise SEQ ID NO: 13.
[0094] In some embodiments of any of the aspects described herein, a linker can comprise an intact second luciferase polypeptide located between the N-terminal reporter protein domain and at least one cleavage site. In some embodiments of any of the aspects described herein, a linker can comprise an intact second luciferase polypeptide located between the N-nanoi.159 and the BoNT cleavage site.
[0095] In some embodiments of any of the aspects described herein, the binding fragment can be located N-terminal of at least one cleavage site. In some embodiments of any of the aspects described herein, the binding fragment can be located between the N-nanoi-i59 and the BoNT cleavage site. In some embodiments of any of the aspects described herein, the linker can comprise, from N-terminal to C-terminal, at least one binding fragment, at least one spacer, and at least one cleavage site. In some embodiments of any of the aspects described herein, the linker can comprise, from N-terminal to C-terminal, at least one binding fragment, at least one spacer, and at least one BoNT cleavage site.
[0096] In some embodiments of any of the aspects described herein, a linker can comprise, from N-terminus to C-terminus, one or more spacers and at least one cleavage site. In some embodiments of any of the aspects described herein, a linker can comprise, from N-terminus to C-terminus, one or more spacers, at least one cleavage site, and one or more spacers. In some embodiments of any of the aspects described herein, a linker can comprise, from N-terminus to C-terminus, at least one cleavage site, and one or more spacers. In some embodiments of any ofthe aspects described herein, a linker can comprise one or more spacers located between the BoNT cleavage site and the N-nanoi.159, between the neurotoxin cleavage site and the C-nanoi6o-no, or a combination thereof.
[0097] In some embodiments of any of the aspects described herein, the linker can comprise a spacer located between a second luciferase polypeptide and a cleavage site. In some embodiments of any of the aspects described herein, the linker can comprise, from N-terminal to C-terminal, a second luciferase polypeptide, at least one spacer, and at least one cleavage site. In some embodiments of any of the aspects described herein, the linker can comprise a spacer located between the second luciferase polypeptide and the BoNT cleavage site.
[0098] In some embodiments of any of the aspects described herein, the single chain polypeptide can further comprise a polyhistidine affinity tag, e.g., His6 (SEQ ID NO: 12). In some embodiments of any of the aspects described herein, the polyhistidine affinity tag is located at the C-terminus of the polypeptide, e.g., C-terminal of the reporter protein C-terminal domain.
[0099] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising: a) amino acids 1-159 of NANOLUC™ luciferase (N-nanoi-159); b) a linker located C-terminal to the N-nanoi.159 comprising: i) a first spacer of 5 to 15 amino acids; ii) a binding fragment comprised of amino acids 529-566 of SV2C located C-terminal to the first spacer; iii) a second spacer located C-terminal to the binding fragment; iv) a BoNT cleavage site comprising amino acids 141-206 of human SNAP25b located C-terminal to the second spacer; iv) a third spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site; and c) amino acids 160-170 of NANOLUC™ luciferase (C-nano^o-no) located C-terminal to the linker; wherein the linker functionally j oins the N-nanoi-i59 and the C-nanoi6o-i7o to generate a functional luciferase fusion protein. In some embodiments of any of the aspects described herein, the polypeptide further comprises a polyhistidine affinity tag C-terminal of the amino acids 160-170 of NANOLUC™ luciferase (C-nanoieo-no).
[00100] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising: a) amino acids 1-159 of NANOLUC™ luciferase (N-nanoi.159); b) a linker located C-terminal to the N-nanoi-i59 comprising: i) a first spacer from 5 to 15 amino acids; ii) a BoNT cleavage site comprising amino acids 141-206 of human SNAP25b located C-terminal to the first spacer; iii) a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site; and c) amino acids 160-170 of NANOLUC™ luciferase (C-nanoieo-no) located C-terminal to the linker; wherein the linker functionally joins the N-nanoi.159 and the C-nanoieo-no to generate a functional luciferase fusion protein. In some embodiments of any of the aspects described herein, the polypeptide further comprises a polyhistidine affinity tag C-terminal of the amino acids 160-170 of NANOLUC™ luciferase (C-nano160-i7o)-
[00101] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising: a) amino acids 1-159 of NANOLUC™ luciferase (N-nanoi.^9); b) a linker located C-terminal to the N-nanoi-i59 comprising: i) a first spacer of 5 to 15 amino acids; ii) a BoNT cleavage site comprising amino acids 35-96 of human VAMPl located C-terminal to the first spacer; iii) a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site; and c) amino acids 160-170 of NANOLUC™ luciferase (C-nanoi6o-i7o) located C-terminal to the linker; wherein the linker functionally joins the N-nanoi-159 and the C-nano^o-no to generate a functional luciferase fusion protein. In some embodiments of any of the aspects described herein, the polypeptide further comprises a polyhistidine affinity tag C-terminal of the amino acids 160-170 of NANOLUC™ luciferase (C-nanoi60-i7o).
[00102] In one aspect of any of the embodiments, described herein is a single chain polypeptide comprising: a) amino acids 1-159 of NANOLUC™ luciferase (N-nanoi.159); b) a linker located C-terminal to the N-nanoi-159 comprising: i) a second functional luciferase polypeptide; ii) a first spacer of 5 to 15 amino acids located C-terminal of the second luciferase polypeptide; iii) a BoNT cleavage site comprising amino acids 1-206 of human SNAP25b (e.g. SEQ ID NO: 14) located C-terminal to the first spacer; iv) a second spacer of 5 to 15 amino acids located C- terminal to the BoNT cleavage site; and c) amino acids 160-170 of NANOLUC™ luciferase (C- nanoi6o-no) located C-terminal to the linker; wherein the linker functionally joins the N-nanoi-159 and the C-nanoi6o-i7o to generate a functional luciferase fusion protein.
[00103] In some embodiments of any of the aspects described herein, the polypeptide further comprises a polyhistidine affinity tag C-terminal of the amino acids 160-170 of NANOLUC™ luciferase (C-nanoi6o-i7o)-
[00104] Table 2Luciferase HFKVILPYGTLVIDGVTPNMLNYFGRPYEGIAVFDGKKITVTGTL WNG KIIDERLITPDGSMLFRVTINSVTGYRLFEEILN-nanol- MVFTLEDFVGDWEQTAAYNLDQVLEQGGVSSLLQ LAVSVTPI 2 159 QRIVRSGENALKIDIHVIIPYEGLSADQMAQIEEVFKVVYPVDDHHFKVILPYGTLVIDGVTP MLNYFGRPYEGIAVFDGKKITVTGTL WNG KIIDERLITPDGSMLFRVTINSC-170 VTGYRLFEEIL 3-nanoieo141-206 of ARE EMDENLEQVSGIIG LRHMALDMGNEIDTQNRQIDRIMEK 10 SNAP25b ADSNKTRIDEANQRATKMLGSG(human andrat)529-566 of NT YFKNC TFIDT VFDNTDFEP YKFID SEFKNC SFFHNK 11 humanSV2CFirefly MEDAKNIKKGPAPFYPLEDGTAGEQLHKAMKRYALVPGTIAFT 13 luciferase DAHIEVDITYAEYFEMSVRLAEAMKRYGLNTNHRIVVCSENSLQFFMPVLGALFIGVAVAPANDIYNERELLNSMGISQPTVVFVSKKGLQKILNVQKKLPIIQKIIIMD SKTDYQGFQ SMYTF VT SHLPPGFNEYDFVPESFDRDKTIALFMNSSGSTGLPKGVALPHRTACVRFSHARDPIFGNQIIPDTAILSVWFHHGFGMFTTLGYLICGFRVVLMYRFEEELFLRSLQDYKIQSALLVPTLFSFFAKSTLIDKYDLSNLHEIASGGAPLSKEVGEAVAKRFHLPGIRQGYGLTETTSAILITPEGDDKPGAVGKVVPFFEAKVVDLDTGKTLGVNQRGELCVRGPMIMSGYVNNTPEATNALIDKDGWLHSGDIAYWDEDEHFFIVDRLKSLIKYKGYQVAPAELESILLQHPNIFDAGVAGLPDDDAGELPAAVVVLEHGKTMTEKEIVDYVASQVTTAKKLRGGVVFVDEVPKGLTGKLDARKIREILIKAKKGGKIAVHuman MAEDADMRNELEEMQRRADQLADESLESTRRMLQLVEESKDA 14SNAP25b GIRTL\TVILDEQGEQLERIEEGMDQINKDMKEAEKNLTDLGKFC(NCBI GLCVCPCNKLKSSDAYKKAWGNNQDGVVASQPARVVDEREQReference MAI S GGFIRRVTND ARENEMDENLEQ VS GIIGNLRHMALDMGNSequence: EIDTQNRQIDRIMEKAD SNKTRIDEANQRATKMLGSGNP 570824.1)Sensor 1 ATGGTCTTCACACTCGAAGATTTCGTTGGGGACTGGGAACAG 15DNA ACAGCCGCCTACAACCTGGACCAAGTCCTTGAACAGGGAGGTsequence GTGTCCAGTTTGCTGCAGAATCTCGCCGTGTCCGTAACTCCGATCCAAAGGATTGTCCGGAGCGGTGAAAATGCCCTGAAGATCGACATCCATGTCATCATCCCGTATGAAGGTCTGAGCGCCGACCAAATGGCCCAGATCGAAGAGGTGTTTAAGGTGGTGTACCCTGTGGATGATCATCACTTTAAGGTGATCCTGCCCTATGGCACACTGGTAATCGACGGGGTTACGCCGAACATGCTGAACTATTTCGGACGGCCGTATGAAGGCATCGCCGTGTTCGACGGCAAAAAGATCACTGTAACAGGGACCCTGTGGAACGGCAACAAAATTATCGACGAGCGCCTGATCACCCCCGACGGCTCCATGCTGTTCCGAGTAACCATCAACAGtgggagttccGGTGGTGGCGGGAGCGGAGGTGGAGGctcgAGCGGTgGAGCTCagAACACCTACTTCAAGAACTGCACATTTATTGACACTGTTTTTGACAACACAGATTTTGAGCCATATAAATTCATTGACAGTGAATTTAAAAACTGCTCGTTTTTTCACAACAAGGGGGGCGGAGGTTCCGCCCGGGAAAATGAAATGGATGAAAACCTAGAGCAGGTGAGCGGCATCATCGGAAACCTCCGTCATATGGCCCTAGACATGGGCAATGAGATTGACACCCAGAATCGCCAGATTGACAGGATCATGGAGAAGGCTGACTCCAACAAAACCAGAATTGATGAAGCCAACCAACGTGCAACAAAGATGCTGGGAAGTGGTggGAATTCtggcTCGAGcGGTGGTGGCGGGAGCGGAGGTGGAGGGtcgtcaGGTGT GAC C GGC T AC C GGC TGT TC GAGGAGATTCTGGCGGCCGCACTCGAGCACCACCACCACCACCACTGAHuman MSAPAQPPAE GTEGTAPGGG PPGPPPNMTS RRLQQTQAQ 16 VAMP1 VEEVVDIIRV NVDKVLERDQ KLSELDDRAD ALQAGASQFESSAAKLKRKY VVW KCKMMIM LGAICAIIVV VIVIYFFTAmino acids GEGKEDAF SKLKQKFMNELHK 17 32-52 ofSYT1Amino acids GESQEDMFAKLKEKFFNEINK 18 40-60 ofSYT2Amino acids LSELDDRADAL QAGASQFETS AAKLKRK 19 60-87 ofhumanVAMP2Amino acids LSELDDRA DALQAGASQFETS AAKLKRK 20 43-70 ofhumanVAMP3Amino acids LSELDDRAD ALQAGASQFE SS AAKLKRK 21 62-89 ofhumanVAMP 1
Claims
WE CLAIMS1. A single chain polypeptide comprising, from N-terminal to C-terminal:a. an N-terminal fragment of a reporter protein;b. a linker comprising a neurotoxin cleavage site; andc. a C-terminal fragment of the reporter protein;wherein the N-terminal and C-terminal fragments collectively comprise a functional reporter protein sequence; and wherein the linker functionally j oins the N-terminal fragment and C-terminal fragment to generate a functional reporter fusion protein.
2. The single chain polypeptide of claim 1, wherein the reporter protein is a luciferase protein.
3. A single chain polypeptide comprising:a. a N-terminal domain comprising a sequence with at least 90% sequence identity to amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi-159);b. a linker comprising a neurotoxin cleavage site located C-terminal to the N-nanoi.159; andc. a C-terminal domain having a sequence with at least 90% sequence identity amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nano^o-ivo) located C- terminal to the linker;wherein the linker functionally joins the N-nanoi.159 and the C-nanoi6o-i7o to generate a functional luciferase fusion protein.
4. A single chain polypeptide comprising:a. a N-terminal domain comprising a sequence having less than 10 amino acidresidues substitutions, deletions, or additions relative to amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi.i59);c. a C-terminal domain having a sequence having less than 3 amino acid residues substitutions, deletions, or additions relative to amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nanoieo-no) located C-terminal to the linker;wherein the linker functionally joins the N-nanoi.159 and the C-nanOi6o.no to generate a functional luciferase fusion protein.
5. The single chain polypeptide of any of claims 3-4, whereinthe N-terminal domain has the sequence of amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi-i59) and the C-terminal domain has the sequence of amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nanoi60.no).
6. The single chain polypeptide of any of claims 1-5, wherein the neurotoxin cleavage site is a C. botulinum neurotoxin (BoNT) and / or a Tetanus neurotoxin cleavage site.
7. The single chain polypeptide of any of claims 1-6, wherein the linker further comprises one or more spacers located between the BoNT cleavage site and the N-terminal fragment or domain , between the neurotoxin cleavage site and the C-terminal fragment or domain, or a combination thereof.
8. The single chain polypeptide of any of claims 1-7, wherein the linker further comprises a binding fragment of a receptor for the BoNT and / or a tetanus neurotoxin.
9. The single chain polypeptide of claim 8, wherein the binding fragment is located between the N-terminal fragment or domain and the BoNT cleavage site.
10. The single chain polypeptide of any of claims 8-9, wherein the linker further comprises a spacer located between the binding fragment and the BoNT cleavage site.1 1. The single chain polypeptide of any of claims 1-10, wherein at least one spacer is comprised of glycine and serine.
12. The single chain polypeptide of any of claims 1-1 1, wherein at least one spacer is 5 to 15 amino acids.
13. The single chain polypeptide of any of claims 1-12, wherein at least one spacer is selected from SEQ ID NOs: 4-9.
14. The single chain polypeptide of any of claims 6-13, wherein the BoNT is A, E, C, B, D, F or G.
15. The single chain polypeptide of any of claims 6-14, wherein the BoNT cleavage site is from a SNARE protein.
16. The single chain polypeptide of claim 15, wherein the SNARE protein is SNAP-25, synaptobrevin (VAMP), or syntaxin.
17. The single chain polypeptide of any of claims 6-16, wherein the BoNT cleavage site is amino acids 141-206 of human SNAP-25b.
18. The single chain polypeptide of any of claims 6-16, wherein the BoNT cleavage site is amino acid 35-96 of human VAMP1.
19. The single chain polypeptide of any of claims 8-17, wherein the receptor is human SV2C.
20. The single chain polypeptide of claim 19, wherein the binding fragment is amino acids 529-566 of human SV2C, or a sequence having at least 90% identity with amino acids 529-566 of human SV2C, or a sequence with no more than 10 amino acid residues substitutions, deletions, or additions relative to amino acids 529-566 of human SV2C.
21. The single chain polypeptide of any one of claims 1-20, further comprising apolyhistidine affinity tag.
22. The single chain polypeptide of claim 21, wherein the polyhistidine affinity tag is located at the C-terminus of the polypeptide.
23. The single chain polypeptide of any of claims 1-22, wherein the linker further comprises an intact second luciferase polypeptide located between the N-terminal fragment or domain and the BoNT cleavage site.
24. The single chain polypeptide of claim 23, wherein the second luciferase polypeptide is firefly luciferase (e.g., Photinus pyralis), bacterial luciferase (e.g., Vibrio fischeri, Vibrio harveyi), sea pansy luciferase (Renilla reniformis), dinoflagellate luciferase, Gaussia luciferase, or copepod luciferase.
25. The single chain polypeptide of claim 23 or 24, wherein the linker further comprises a spacer located between the second luciferase polypeptide and the BoNT cleavage site.
26. The single chain polypeptide of claim 25, wherein the spacer is from 5 to 15 amino acids.
27. The single chain polypeptide of claim 25 or 26, wherein the spacer isGSSGGGGSGGGGSSG (SEQ ID NO: 4), GSSGGGGSGGGSSG (SEQ ID NO: 5), or GGGGS (SEQ ID NO: 6).
28. A single chain polypeptide comprising:a. amino acids 1-159 of the luciferase of SEQ ID NO: 1 b. a linker located C-terminal to the N-nanoi.isg comprising:i. a first spacer of 5 to 15 amino acids;ii. a binding fragment comprised of amino acids 529-566 of SV2C located C- terminal to the first spacer;iii. a second spacer located C-terminal to the binding fragment;iv. a BoNT cleavage site comprising amino acids 141-206 of humanSNAP25b located C-terminal to the second spacer;v. a third spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site; andc. amino acids 160-170 of the luciferase of SEQ ED NO: 1 (C-nanoi6o-no) located C- terminal to the linker;29. A single chain polypeptide comprising:a. amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi-isg); b. a linker located C-terminal to the N-nanoi-i59 comprising:i. a first spacer from 5 to 15 amino acids;ii. a BoNT cleavage site comprising amino acids 141-206 of humanSNAP25b located C-terminal to the first spacer;iii. a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site; andc. amino acids 160-170 of the luciferase of SEQ ED NO: 1 (C-nano^o-no) located C- terminal to the linker;30. A single chain polypeptide comprising:a. amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi-^);ii. a BoNT cleavage site comprising amino acids 35-96 of humanVAMP1 located C-terminal to the first spacer;wherein the linker functionally joins the N-nanoi.159 and the C-nanoi6o-no to generate a functional luciferase fusion protein.
31. A single chain polypeptide comprising:a. amino acids 1-159 of the luciferase of SEQ ID NO: 1 (N-nanoi.b. a linker located C-terminal to the N-nanoi-isg comprising:i. a second functional luciferase polypeptide;ii. a first spacer of 5 to 15 amino acids located C-terminal of the second luciferase polypeptide;iii. a BoNT cleavage site comprising amino acids 1-206 of human SNAP25b located C-terminal to the first spacer; iv. a second spacer of 5 to 15 amino acids located C- terminal to the BoNT cleavage site; andc. amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C- nanoi6o-no) located C-terminal to the linker;32. The single chain polypeptide of any of claims 28-31, wherein one or more spacers are GSSGGGGSGGGGSSG (SEQ ID NO: 4), GSSGGGGSGGGSSG (SEQ ID NO: 5), or GGGGS (SEQ ID NO: 6)33. The single chain polypeptide of any of claims 28-32, further comprising a His6 sequence (SEQ ID NO: 12) located at the C-terminus.
34. A nucleic acid comprising a nucleotide sequence that encodes the single chain polypeptide of any one of claims 1-33.
35. A nucleic acid vector comprising the nucleic acid of claim 34.
36. The nucleic acid vector of claim 35 that is an expression vector and comprises the nucleic acid sequence in expressible form.
37. The nucleic acid vector of claim 36 that is selected from the group consisting of a viral expression vector, a prokaryotic expression vector, a yeast expression vector, an insect expression vector, or a mammalian expression vector.
38. A cell comprising the nucleic acid of claim 34 or the nucleic acid vector of claims 35-37.
39. The cell of claim 38, that expresses the single chain polypeptide of any one of claims 1-33.
40. The cell of claim 39, that is a prokaryotic cell, a yeast cell, an insect cell, or an animal cell.
41. A method for determining the potency of a botulinum neurotoxin, comprising:a) contacting the neurotoxin to a single chain polypeptide of any of claims 1- 33 under conditions appropriate for BoNT activity; andb) determining the luciferase activity of the polypeptide, as compared to a reference, thereby determining the potency.
42. A method for detecting C. botulinum neurotoxin (BoNT) activity in a sample, comprising:a) contacting the sample to a single chain polypeptide of any of claims 1-33, under conditions appropriate for BoNT activity; andb) determining luciferase activity of the polypeptide, as compared to luciferase activity of the polypeptide in the absence of the sample, wherein a decrease of luciferase activity indicates BoNT activity in the sample.
43. The method of any of claims 41-42 that is performed in vitro.
44. The method of any of claims 41-43, wherein contacting occurs in a buffer of 50mM HEPES, 20 μΜ ZnCl2, 2 mM DTT, 1 mg / ml BSA, pH 7.1.
45. The method of claims 41-44, wherein the concentration of the single chain polypeptide contacted to the sample is from about 30 nM to 300 nM.
46. The method of claim 45, wherein the concentration of single chain polypeptide contacted to the sample is about 30 nM.
47. The method of any of claims 41-46, wherein the luciferase activity is determined by addition of luciferase substrate to the single chain polypeptide and quantitative measurement of a luminescent signal produced.
48. The method of any of claims 41-47, wherein the conditions comprise incubation at about 37°C for a period of from about 1 hour to about 36 hours.
49. The method of any of claims 41-48, wherein the conditions comprise incubation at about 37°C for a period of from about 1 hour to about 24 hours.
50. The method of any of claims 41-49, wherein the conditions comprise incubation at about 37°C for a period of from about 4 hours to about 24 hours.
51. The method of any of claims 41-50, wherein the linker comprises a first spacer of 5 to 15 amino acids, a binding fragment of amino acids 529-566 of human SV2C located C-terminal to the first spacer and N-terminal to the BoNT cleavage site, and a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site, wherein the BoNT cleavage site comprises amino acids 141-206 of human SNAP25.
52. The method of any of claims 41-50, wherein the linker comprises a first spacer of 5 to 15 amino acids located N-terminal to the BoNT cleavage site, and a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site, wherein the BoNT cleavage site comprises amino acids 141-206 of human SNAP25.
53. The method of any of claims 41-50, wherein the linker comprises a first spacer of 5 to 15 amino acids located N-terminal to the BoNT cleavage site, a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site, wherein the BoNT cleavage site comprises amino acids 35-96 of human VAMP1.
54. The method of any of claims 41-53, wherein the single chain polypeptide is expressed by a neuronal cell and the method further comprises, after the contacting step:incubating the neuronal cells for a period of from about 12 hours to about 60 hours and harvesting lysate from the neuronal cells.
55. A method for detecting C. botulinum neurotoxin (BoNT) activity in a sample, comprising:a) contacting the sample to neuronal cells expressing a single chain polypeptide comprising:amino acids 160-170 of the luciferase of SEQ ID NO: 1 (C-nano^o-no), separated and functionally joined by a linker comprising a BoNT cleavage site located C- terminal to the N-nanoi.159 and N-terminal to the C-nanoi6o-i7o ;b) incubating the neuronal cells for a period of from about 12 hours to about 60 hours;c) harvesting lysate from the neuronal cells;d) measuring luciferase activity in the lysate, as compared to luciferase activity in identically treated neuronal cells in the absence of the sample, wherein a decrease in the luciferase activity indicates BoNT activity in the sample.
56. The method of any of claims 41-55, wherein the linker further comprises an intact second luciferase polypeptide located between the N-nanoi-15 and the cleavage site.
57. The method of claim 56, wherein the second luciferase polypeptide firefly luciferase (photinus pyralis), bacterial luciferase (vibrio fischiri, vibrio harveyi), sea pansy luciferase (renilla reniformis), dinoflagellate luciferase, gaussia luciferase, or copepod luciferase.
58. The method of any of claims 56-57, wherein the luciferase activity of the second luciferase polypeptide in the sample is determined and used as an indicator of total single chain polypeptide present in the harvested lysate.
59. The method of any of claims 54-58, wherein the neuronal cells express the single chain polypeptide from a viral expression vector.
60. The method of claim 59, wherein the single chain polypeptide is expressed for 6 days prior to step a).
61. The method of claim 59, wherein the viral expression system is a lentivirus expression system.
62. The method of any of claims 54-61, wherein the incubating step is about 48 hours.
63. The method of any of claims 54-62, wherein the harvesting step is by addition of a lysis buffer.
64. The method of any one of claims 41-63, wherein the BoNT cleavage site is from SNAP-25, synaptobrevin (VAMP), or syntaxin.
65. The method of any one of claims 41-64, wherein the BoNT cleavage site is specifically recognized by BoNT A, E and C, or is specifically recognized by BoNT B, D, F and G.
66. The method of any one of claims 41-65, wherein a combination of single chain polypeptides having different BoNT cleavage sites are used.
67. The method of claims 41-66, wherein the BoNT cleavage site is a.a.141-206 of human SNAP-25, or a.a. 35-96 of human VAMP1, a.a. 1-206 of human SNAP35, or a.a. 1-96 of VAMP168. The method of any one of claims 41-67, wherein the linker further comprises a binding fragment of a BoNT receptor.
69. The method of claim 68, wherein the receptor is SV2C.
70. The method of any of claims 68-69, wherein the binding fragment comprises amino acids 529-566 of human SV2C.
71. The method of any of claims 41-70, wherein the linker comprises a second luciferase polypeptide, a first spacer of 5 to 15 amino acids located C-terminal of the second luciferase polypeptide and N-terminal of the BoNT cleavage site, a second spacer of 5 to 15 amino acids located C-terminal to the BoNT cleavage site, wherein the BoNT cleavage site comprises amino acid 1-206 of human SNAP25 and is located C-terminal to the first spacer.
72. The method of any of claims 41-71, wherein measuring luciferase activity is by addition of a substrate specific for the luciferase and quantitative detection of the resulting luminescent signal.
73. The method of claim 72, wherein the substrate for the luciferase of SEQ ID NO: 1 is furimazine (2-furanylmethyl-deoxy-coelenterazine).
74. A kit comprising:a) one or more single chain polypeptides described in claims 1-33, with each or a combination of the single chain polypeptides packaged into a separate container; b) one or more nucleic acids or nucleic acid vectors described in claims 34 -37, with each or a combination of the nucleic acids or nucleic acid vectors packaged into a separate container; and / orc) one or more cells described in claims 38-40 with each or a combination of the cells packaged into a separate container.
75. A kit according to claim 74, further comprising a luciferase substrate packaged into a separate container.
